Core Viewpoint - Jimin Health's stock has experienced significant volatility, with a recent closing price increase leading to a trading halt, despite the company reporting substantial losses in its financial performance [1] Summary by Relevant Sections Stock Performance - Jimin Health's stock closed at a limit up today, with a turnover rate of 16.96% - From September 8 to 11, 2025, the cumulative closing price increase reached 33.78% - The stock's deviation from the Shanghai A-share index over the past 30 trading days amounted to 94.72% [1] Financial Performance - For the fiscal year 2024, the net profit attributable to the parent company was -59.71 million yuan - In the first half of 2025, the net profit attributable to the parent company was -52.70 million yuan - The company is currently in a loss-making state, with no changes in its main business operations [1] Market Behavior - The stock has shown significant abnormal trading behavior, with multiple days of sharp price increases and decreases - There is a potential risk of a rapid decline in stock price in the future, given the disconnect between stock price trends and operational performance [1]

Core Viewpoint - The company, Jimin Health, has issued a stock trading risk warning as its stock price has experienced significant volatility, with a recent closing price increase leading to concerns about potential rapid declines in the future [1] Summary by Relevant Sections Stock Performance - The company's stock closed at a daily limit increase, with a turnover rate of 16.96% [1] - From September 8 to September 11, 2025, the cumulative closing price increase reached 33.78% [1] - Over the past 30 trading days, the stock's increase has deviated from the Shanghai A-share index by a cumulative 94.72% [1] Trading Anomalies - The stock has shown significant fluctuations, with multiple trading days experiencing consecutive large increases and decreases [1] - There is a clear indication of abnormal trading activity, suggesting potential risks for investors [1] Financial Performance - The company is currently in a state of loss, with no changes in its main business operations [1] - The stock price trend is noticeably diverging from the company's operational performance [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重大风险提示： ●公司股票今日收盘再次涨停，换手率达到 16.96%，自 2025 年 9 月 8 日至 11 日，收盘价格累计涨幅达 33.78%，近 30 个交易日涨幅与上证 A 指偏离值累计 达 94.72%，剔除大盘和板块整体因素后的实际涨跌幅波动较大，多个交易日连续 大涨大跌，股票交易存在明显异常，后续可能随时有快速下跌风险。 ●2024 年度归属于母公司所有者的净利润为-5,971.17 万元；2025 年半年度， 公司实现归属于母公司所有者的净利润为-5,269.59 万元。公司业绩处于亏损状态， 主营业务未发生变化，目前股价走势与经营业绩趋势明显偏离。 ●公司控股股东于 2025 年 9 月 5 日披露了减持股份计划，计划以集中竞价交 易方式和大宗交易方式减持公司合计不超过 15,752,718 股股份，即不超过公司总 股本的 3%。 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 证券代码：603222 证券简称：济民健康 公告编号：2025-0 ...

每经AI快讯，9月11日，济民健康（603222）(603222.SH)公告称，公司股票今日收盘再次涨停，换手率 达到16.96%，自2025年9月8日至11日，收盘价格累计涨幅达33.78%，近30个交易日涨幅与上证A指偏离 值累计达94.72%，剔除大盘和板块整体因素后的实际涨跌幅波动较大，多个交易日连续大涨大跌，股 票交易存在明显异常，后续可能随时有快速下跌风险。 ...

济民健康股票交易风险提示公告，公司股票今日收盘再次涨停，换手率达到16.96%，自2025年9月8日 至11日，收盘价格累计涨幅达33.78%，近30个交易日涨幅与上证A指偏离值累计达94.72%，剔除大盘和 板块整体因素后的实际涨跌幅波动较大，多个交易日连续大涨大跌，股票交易存在明显异常，后续可能 随时有快速下跌风险。 ...

Group 1 - Jimin Health has experienced a significant increase, with 6 consecutive trading limits reached in 12 days [1] - Shutai Shen has risen over 7%, indicating strong market interest [1] - Hot景生物 has seen an increase of over 5%, reflecting positive investor sentiment [1] Group 2 - Other companies such as Meidi Xi, Guangsheng Tang, and Borui Pharmaceutical have also shown upward trends in their stock prices [1]

Core Viewpoint - Jimin Health (603222) experienced a significant increase in stock price, reaching the daily limit, with a trading volume of 1.202 billion yuan and a fluctuation of 18.35% [1][2]. Trading Activity - The stock was listed on the trading board due to its daily fluctuation of 18.35%, with a total net purchase by brokerage seats amounting to 66.0795 million yuan [2]. - The top five brokerage seats accounted for a total transaction of 289 million yuan, with a buying amount of 178 million yuan and a selling amount of 111 million yuan, resulting in a net purchase of 66.0795 million yuan [2]. - The largest buying brokerage was Huafu Securities, with a purchase amount of 59.0385 million yuan, while the largest selling brokerage was CITIC Securities, with a selling amount of 46.6849 million yuan [2]. Stock Performance - Over the past six months, the stock has appeared on the trading board 13 times, with an average price increase of 2.92% the day after being listed and an average increase of 10.07% in the following five days [3]. - The stock saw a net inflow of 237 million yuan from major funds today, with a significant inflow of 263 million yuan from large orders, while smaller orders saw a net outflow of 25.9314 million yuan [3]. - In the past five days, the net inflow of major funds totaled 290 million yuan [3]. Financing and Margin Data - As of September 10, the stock's margin trading balance was 197 million yuan, with a financing balance of 197 million yuan and a securities lending balance of 115,000 yuan [3]. - In the past five days, the financing balance increased by 224,900 yuan, reflecting a growth rate of 0.11%, while the securities lending balance increased by 22,900 yuan, with a growth rate of 24.84% [3]. Financial Results - According to the semi-annual report released on August 21, the company achieved a revenue of 366 million yuan in the first half of the year, representing a year-on-year decline of 21.30%, and reported a net loss of 52.6959 million yuan [3].

Market Overview - The Shanghai Composite Index rose by 1.65% on September 11, with 31 out of 41 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.39% and 5.96% respectively [2] - The pharmaceutical and biotechnology sector saw a modest increase of 0.25% [2] Capital Flow Analysis - The net inflow of capital in the two markets reached 34.518 billion yuan, with 11 sectors experiencing net inflows [2] - The electronics sector had the highest net inflow of 21.723 billion yuan, corresponding to its 5.96% increase, followed by the computer sector with a net inflow of 8.479 billion yuan and a daily increase of 3.71% [2] Pharmaceutical and Biotechnology Sector Performance - Within the pharmaceutical and biotechnology sector, there were 474 stocks, with 350 stocks rising and 111 stocks declining [3] - The top three stocks with the highest net inflow were Jimin Health (2.37 billion yuan), Shutai Shen (1.55 billion yuan), and Rejing Bio (1.41 billion yuan) [3] - The sector experienced a net outflow of 3.975 billion yuan, with the largest outflows from WuXi AppTec (3.17 billion yuan), BeiGene (2.29 billion yuan), and Zhaoyan New Drug (1.78 billion yuan) [3][5] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +10.02% with a turnover rate of 16.96% and a capital flow of 236.996 million yuan - Shutai Shen: +7.24% with a turnover rate of 10.87% and a capital flow of 155.111 million yuan - Rejing Bio: +11.40% with a turnover rate of 6.65% and a capital flow of 140.912 million yuan [4] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - WuXi AppTec: -2.41% with a turnover rate of 4.06% and a capital outflow of -317.3795 million yuan - BeiGene: -3.73% with a turnover rate of 11.42% and a capital outflow of -229.1395 million yuan - Zhaoyan New Drug: -2.88% with a turnover rate of 9.44% and a capital outflow of -178.0592 million yuan [5]

Group 1 - The medical device ETF (562600) opened lower but closed up by 1.25%, with leading stocks such as Hotspring Bio rising by 11.40% and Jimin Health and Zhend Medical hitting a strong limit up of 10% [1] - The National Medical Products Administration (NMPA) has focused on key areas such as medical robots, high-end medical imaging, AI medical devices, and new biological materials, approving 52 innovative products this year, totaling 367 approved innovative products to date [1] - Recent high-level discussions emphasized principles like "anti-involution" and "optimizing centralized procurement without solely focusing on low prices," indicating a clear signal for policy shifts supporting the innovative medical device industry [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device sector, tracking the CSI All Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - The medical device sector accounts for a significant 89.34% of the index, indicating a concentrated focus on capturing the development dividends in this field [2] - As of the first quarter of 2025, the top ten holdings in the medical device ETF (562600) include Mindray Medical and United Imaging, which together account for 22.3% of the ETF [2]

Group 1 - The innovative drug concept stocks have shown signs of recovery, with Ji Min Health achieving a six-day consecutive increase [1] - Shu Tai Shen has risen over 7%, while Rejing Bio has increased by more than 5% [1] - Other stocks such as MediX, Guangsheng Tang, and Borui Pharmaceutical have also experienced upward movement [1]